Form 4: Co-CEO Heyburn's Tax-Related Stock Sale

Strata Critical Medical's Co-CEO and CFO, William A. Heyburn, reported a disposition of 35,348 shares of Class A common stock for tax withholding purposes.

Summary

• William A. Heyburn, Co-CEO and CFO of Strata Critical Medical, Inc. (SRTA), reported a transaction on September 10, 2025.
• The transaction involved the disposition of 35,348 shares of Class A common stock, with a par value of $0.0001 per share.
• These shares were withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The shares were valued at $4 per share for the purpose of this tax withholding transaction.
• Following this reported transaction, Heyburn beneficially owns 1,305,497 shares of Class A common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary event related to executive compensation and tax obligations, not indicative of operational performance or a change in investment sentiment by the insider.

Positives

• The disposition of shares was non-discretionary, solely for tax withholding purposes related to the vesting of restricted stock units, rather than a voluntary sale indicating a lack of confidence.

Negatives

• A reduction of 35,348 shares in direct beneficial ownership by a key executive, even for tax purposes, slightly decreases the insider's direct equity alignment with shareholders.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a report of a past insider transaction.

Industry Context

This Form 4 reports a routine insider transaction common in executive compensation. The disposition of shares for tax withholding upon the vesting of restricted stock units is a standard practice across industries for executives receiving equity-based compensation.

Comparison to Industry Standards

• The reported transaction is a standard tax withholding event associated with the vesting of Restricted Stock Units (RSUs), a common component of executive compensation packages across various industries. This practice is consistent with how equity compensation is typically managed for tax purposes for executives at publicly traded companies.

Stakeholder Impact

• Shareholders: The transaction represents a minor, non-discretionary reduction in insider ownership, which is a standard part of equity compensation and tax management. No significant impact on shareholder value is implied.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares by an insider to cover tax obligations upon the vesting of restricted stock units. It does not reflect a change in the insider's investment conviction or the company's fundamental performance. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

Strata Critical Medical, SRTA, William A. Heyburn, Form 4, insider transaction, stock disposition, tax withholding, restricted stock units, RSU vesting, executive compensation